We are live on ! Find out more
MB

MPM BioImpact Portfolio holdings

AUM $1.29B
1-Year Est. Return 141.72%
This Fund
S&P 500
This Quarter Est. Return
+6.98%
1 Year Est. Return
+141.72%
3 Year Est. Return
+440.65%
5 Year Est. Return
+290.21%
10 Year Est. Return
–
AUM
$577M
AUM Growth
-$4.53M
Cap. Flow
+$3.09M
Cap. Flow %
0.53%
Top 10 Hldgs %
45.32%
Holding
51
New
8
Increased
10
Reduced
20
Closed
7

Top Buys

Rank Stock Value
1
DYN icon
Dyne Therapeutics
DYN
+$15.9M
2
TARS icon
Tarsus Pharmaceuticals
TARS
+$15.4M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$13.7M
4
RCKT icon
Rocket Pharmaceuticals
RCKT
+$11.6M
5
DBVT
DBV Technologies
DBVT
+$9.33M

Top Sells

Rank Stock Value
1
LNTH icon
Lantheus
LNTH
+$22.7M
2
UTHR icon
United Therapeutics
UTHR
+$18.2M
3
ITOS
iTeos Therapeutics
ITOS
+$10.4M
4
TWST icon
Twist Bioscience
TWST
+$10.3M
5
NTRA icon
Natera
NTRA
+$9.06M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CGEM icon
1
Cullinan Oncology
CGEM
$1.06B
$57.6M 9.98%
7,648,268
– –
MDGL icon
2
Madrigal Pharmaceuticals
MDGL
$12.6B
$30.4M 5.27%
100,415
– –
ZLAB icon
3
Zai Lab
ZLAB
$2.07B
$26.1M 4.51%
745,060
-88,599
-11% -$2.91M
GH icon
4
Guardant Health
GH
$19.1B
$23M 3.99%
442,656
– –
SPRY icon
5
ARS Pharmaceuticals
SPRY
$579M
$22.7M 3.94%
1,303,399
-9,705
-0.7% -$140K
EWTX icon
6
Edgewise Therapeutics
EWTX
$4.28B
$22.6M 3.91%
1,720,741
+615,297
+56% +$8.87M
RNAM
7
DELISTED
Avidity Biosciences
RNAM
$21.6M 3.74%
760,022
+45,798
+6% +$1.37M
PTCT icon
8
PTC Therapeutics
PTCT
$6.18B
$21.4M 3.71%
438,477
-1,500
-0.3% -$71.2K
TRVI icon
9
Trevi Therapeutics
TRVI
$2.57B
$18.6M 3.23%
3,406,955
-21,411
-0.6% -$133K
ORIC icon
10
Oric Pharmaceuticals
ORIC
$1.17B
$17.6M 3.04%
1,729,378
+329,864
+24% +$2.21M
NTRA icon
11
Natera
NTRA
$36.4B
$16.7M 2.9%
98,924
-58,123
-37% -$9.06M
ALKS icon
12
Alkermes
ALKS
$8.11B
$15.7M 2.72%
549,262
+211,659
+63% +$6.3M
MLTX icon
13
MoonLake Immunotherapeutics
MLTX
$1.56B
$14.8M 2.56%
313,571
-2,478
-0.8% -$101K
MBX
14
MBX Biosciences
MBX
$3.04B
$14.8M 2.56%
1,294,416
+161,466
+14% +$1.64M
CMPX icon
15
Compass Therapeutics
CMPX
$349M
$14.6M 2.53%
5,622,505
-2,820,278
-33% -$5.82M
RARE icon
16
Ultragenyx Pharmaceutical
RARE
$2.46B
$14.4M 2.49%
395,700
-2,745
-0.7% -$99K
JANX icon
17
Janux Therapeutics
JANX
$912M
$14.2M 2.46%
614,282
+47,089
+8% +$1.24M
TARS icon
18
Tarsus Pharmaceuticals
TARS
$2.55B
$13.8M 2.4%
+341,496
New +$15.4M
DYN icon
19
Dyne Therapeutics
DYN
$4.15B
$13.8M 2.39%
+1,446,361
New +$15.9M
VERA icon
20
Vera Therapeutics
VERA
$2.33B
$13.3M 2.3%
563,075
+147,356
+35% +$3.31M
CRNX icon
21
Crinetics Pharmaceuticals
CRNX
$8.88B
$12.3M 2.14%
428,975
-202,989
-32% -$6.27M
RVMD icon
22
Revolution Medicines
RVMD
$38.5B
$11.6M 2.01%
315,722
-1,361
-0.4% -$52.3K
AKBA icon
23
Akebia Therapeutics
AKBA
$338M
$10.5M 1.82%
+2,889,125
New +$7.94M
OLMA icon
24
Olema Pharmaceuticals
OLMA
$977M
$10.1M 1.76%
2,378,762
-551,684
-19% -$2.46M
XENE icon
25
Xenon Pharmaceuticals
XENE
$6.1B
$10.1M 1.75%
323,398
+20,000
+7% +$652K
1
2 3

Similar funds

MCM
Mainstay Capital Management Grand Blanc, Michigan $1.3B AUM 37.8% 1-Year Est. Return
PWP
Private Wealth Partners Mill Valley, California $1.3B AUM 26.2% 1-Year Est. Return
GPCM
Greenbrier Partners Capital Management Dallas, Texas $1.3B AUM 21.43% 1-Year Est. Return
PR
Payden & Rygel Los Angeles, California $1.3B AUM 28.32% 1-Year Est. Return
ACM
AH Capital Management Menlo Park, California $1.29B AUM 26.81% 1-Year Est. Return
PCM
Penn Capital Management Philadelphia, Pennsylvania $1.29B AUM 53.44% 1-Year Est. Return
COCM
Charter Oak Capital Management Portsmouth, New Hampshire $1.29B AUM 13.93% 1-Year Est. Return
MA
MONECO Advisors Fairfield, Connecticut $1.29B AUM 18.01% 1-Year Est. Return

MPM BioImpact's Q2 2025 Portfolio in Review

As of Q2 2025, MPM BioImpact held 51 positions worth $577M, down 0.78% from $582M the previous quarter. Its ten largest holdings account for 45% of the portfolio.

MPM BioImpact's Q2 2025 filing shows 8 new, 10 increased, 20 reduced and 7 closed positions. Its largest new stake was Dyne Therapeutics: 1,446,361 shares worth $13.8M. The largest sale was Lantheus, an estimated $22.7M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • MPM BioImpact's largest Q2 2025 buy was Dyne Therapeutics: 1,446,361 shares worth $13.8M.
  • MPM BioImpact added most to Rocket Pharmaceuticals in Q2 2025, an estimated $11.6M increase.
  • MPM BioImpact's biggest Q2 2025 reduction was Natera, cutting an estimated $9.06M.
  • MPM BioImpact fully exited Lantheus in Q2 2025, selling an estimated $22.7M.
  • MPM BioImpact's ten largest holdings make up 45% of its $577M portfolio in Q2 2025.
  • MPM BioImpact opened 8 new positions and closed 7 in Q2 2025.
  • MPM BioImpact's portfolio value fell 0.78% quarter-over-quarter to $577M.

Based on MPM BioImpact's 13F filing for Q2 2025, filed 14 Aug 2025.